Navigation Links
Simeprevir Administered Once Daily as Part of Combination Therapy Demonstrates Sustained Virologic Response in Treatment-Naive and Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
Date:11/2/2013

                           
In a pooled analysis of the Phase 3 QUEST-1 and QUEST-2 studies, 80 percent of treatment-naive patients treated with simeprevir in combination with pegylated interferon and ribavirin achieved the primary endpoint of sustained virologic response 12 weeks after the end of treatment (SVR12) compared to 50 percent of patients treated with placebo plus pegylated interferon and ribavirin. The pooled analysis found that 61 percent of patients with the IL28B TT genotype, 60 percent of patients with a METAVIR score of F4 and 75 percent of patients with genotype 1a HCV treated with simeprevir combined with pegylated interferon and ribavirin achieved SVR12 compared to 21 percent, 34 percent and 47 percent of patients taking placebo plus pegylated interferon and ribavirin, respectively. Among patients with the genotype 1a Q80K polymorphism at baseline, 58 percent of patients treated with simeprevir combined with pegylated interferon and ribavirin achieved SVR12 compared to 52 percent of patients treated with placebo in combination with pegylated interferon and ribavirin, but the difference was not statistically significant.

Eight percent and 10 percent of patients treated with simeprevir combined with pegylated interferon and ribavirin experienced on-treatment failure and relapse, respectively, compared to 33 percent and 15 percent of patients taking placebo plus pegylated interferon and ribavirin, respectively. Three percent of patients treated with simeprevir discontinued treatment early due to an adverse event compared to two percent of patients treated with placebo.

Analysis from PROMISE Reinforces Efficacy of Simeprevir in Sub-Populations of Patients (Abstract 1092)                    
'/>"/>

SOURCE Janssen R&D Ireland
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Simeprevir Data in Hepatitis C Patients to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
2. Primary Efficacy and Safety Findings from Phase 3 Study of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
3. U.S. FDA Grants Priority Review to Simeprevir (TMC435) for Combination Treatment of Genotype 1 Chronic Hepatitis C
4. Janssen and Johnson & Johnson to Provide Webcast Presentation of Simeprevir Phase 3 Clinical Data Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
5. Findings from Two Phase 3 Studies of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients
6. Janssen Submits New Drug Application to U.S. FDA for Simeprevir (TMC435) for Combination Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C
7. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
8. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
9. MCOs Shifting Control Over Office-Administered Products from Medical to Pharmacy Benefit, Particularly Affecting Rheumatoid Arthritis Therapies
10. American Journal of Medicine Publishes Hypertension Study Comparing the Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone versus Azilsartan Medoxomil Co-administered with Hydrochlorothiazide
11. Daiichi Sankyos Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Most osteoporosis patients want a choice in ... survey* sponsored by Mission Pharmacal Company. The survey, conducted ... online support community, revealed that 74 percent of osteoporosis ... a form other than a pill or a tablet. ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... received commitments from institutional investors to purchase an aggregate ... in an at-the-market registered direct offering, led by a ... into definitive purchase agreements with these investors pursuant to ...
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and distributors ... able to protect their most important business assets, ... ) Because of the highly-competitive ... remains one of the most litigious industry sectors ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... announces that a new market research report is ... Butadiene Market In Americas To 2020 - Recovery ... In The Region ... To 2020 - Recovery In End Use Markets ...
... Reportlinker.com announces that a new market research report is ... Marker Diagnostic Testing Markets ... Publications report is to describe the specific market segment ... cardiac marker testing. This study examines clinical measurement devices ...
Cached Medicine Technology:Reportlinker Adds Butadiene Market In Americas To 2020 - Recovery In End Use Markets Providing Positive Demand Growth In The Region 2Reportlinker Adds Butadiene Market In Americas To 2020 - Recovery In End Use Markets Providing Positive Demand Growth In The Region 3Reportlinker Adds Butadiene Market In Americas To 2020 - Recovery In End Use Markets Providing Positive Demand Growth In The Region 4Reportlinker Adds Butadiene Market In Americas To 2020 - Recovery In End Use Markets Providing Positive Demand Growth In The Region 5Reportlinker Adds Butadiene Market In Americas To 2020 - Recovery In End Use Markets Providing Positive Demand Growth In The Region 6Reportlinker Adds Butadiene Market In Americas To 2020 - Recovery In End Use Markets Providing Positive Demand Growth In The Region 7Reportlinker Adds Butadiene Market In Americas To 2020 - Recovery In End Use Markets Providing Positive Demand Growth In The Region 8Reportlinker Adds Butadiene Market In Americas To 2020 - Recovery In End Use Markets Providing Positive Demand Growth In The Region 9Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 2Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 3Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 4Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 5Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 6Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 7Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 8
(Date:4/18/2014)... 2014) ― A new study in the American ... health-related Google searches reveals a recurring pattern that could ... , Investigators from San Diego State University, the Santa ... analyzed "healthy" Google searches (searches that included the term ... in the U.S. from 2005 to 2012. They found ...
(Date:4/18/2014)... Medicine scientists could lead to potential new treatments for ... scleroderma. , Fibrosis, or scarring, is a hallmark ... and lungs can lead to serious organ damage and, ... therapeutic options centers on findings made by Swati Bhattacharyya, ... role that a specific protein plays in promoting fibrosis. ...
(Date:4/17/2014)... in non-cancerous prostate tissue may have nearly twice the ... no inflammation, according to results of a new study ... Center. , The link between persistent inflammation and cancer ... cancer those with a Gleason score between 7 ... aggressive and rapidly growing prostate cancers. , "What we,ve ...
(Date:4/17/2014)... identified new pain relief targets that could be ... researchers at King,s College London made the discovery ... the periphery of the body. , Dr Marzia ... mechanisms underlying pain generation and our findings could ... effects." , One potential side effect of some ...
(Date:4/17/2014)... study published today in PLOS Pathogens , children ... is common can mount an immune response to infection ... repeated bouts of high fever and illness and partially ... The findings may help researchers develop future interventions that ... parasite. , Each year, approximately 200 million cases of ...
Breaking Medicine News(10 mins):Health News:New research shows people are thinking about their health early in the week 2Health News:New clues on tissue scarring in scleroderma 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:New pain relief targets discovered 2Health News:Study sheds light on how the immune system protects children from malaria 2
... 10 (HealthDay News) -- A positive attitude and a ... to an expert. Women should start preparing when ... begins in the 40s, but can start as early ... of obstetrics/gynecology at Gottlieb Memorial Hospital, Loyola University Health ...
... end of this year, colonoscopy screening will have prevented ... was introduced in Germany. This is the result obtained ... in Heidelberg and his co-authors in their interim assessment ... the German cancer screening program. The authors present their ...
... drinking glasses, and other children,s products constitute an ongoing ... in these products and other changes in policy and ... ACS, Environmental Science & Technology , a semi-monthly ... Massey note that in June the United States government ...
... 9 (HealthDay News) -- Long-term use of androgen deprivation therapy ... broken bones, according to a new study. These findings ... use this therapy in older men with localized disease, the ... men, aged 66 and older, who survived at least five ...
... Bazan, Boyd Professor, Villere Chair, and Director of the Neuroscience ... that Docosahexaenoic acid (DHA), a component of fish oil, ... and promote recovery in an experimental model of acute ischemic ... hours. These findings not only target a new stroke treatment ...
... New research shows a gene-based test for lung ... likely to benefit from CT screening for lung cancer, ... the American Association of Cancer Research,s Ninth Annual Conference ... that included 1,216 lung cancer cases and 1,200 controls ...
Cached Medicine News:Health News:Positive Attitude, Planning May Help Women Through Menopause 2Health News:Fracture Risk Seen With Hormone Therapy for Prostate Cancer 2Health News:Louisiana State University Health Sciences Center research shows fish oil component given up to 5 hours after stroke limits brain damage 2Health News:Louisiana State University Health Sciences Center research shows fish oil component given up to 5 hours after stroke limits brain damage 3Health News:Research shows gene-based test can prioritize smokers for lung cancer CT screening 2Health News:Research shows gene-based test can prioritize smokers for lung cancer CT screening 3
Use to prevent arm or leg drops during surgical procedures. The dimensions are 10"W x 6"H. These come in pairs. Optional Gel pad available (BD2245)...
... Precision Dynamics Corporation offers a ... serving infants to adults. Armboard ... non-woven material assuring easy cleaning ... cross contamination. Choose from three ...
... to fit almost every operating table. 3/D ... the sit of fixation to the operating ... be titled to any position the surgeon ... adjustment of the 3/D Swinger permits rotation ...
Stainless steel construction to withstand sterilization modalities (EtO) Wide angle of view...
Medicine Products: